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To determine whether the number of buprenorphine providers is associated with the number 
opioid related deaths per county; and whether a rural setting in Vermont affects mortality rates 
due to a possible lack of Buprenorphine providers.    
    
Methods  
We compared the incidence of overdose deaths per county to the number of buprenorphine 
providers per county, as listed on the Vermont Department of Health website. Tukey HSD and 
Bonferroni statistical tests were run to measure a linear association between deaths per county 
and city town code (CTC). Grand Isle County was excluded from the analysis due to no deaths.    
    
Results  
Counties with medium provider densities had higher numbers of overdose deaths compared to 
counties with higher and lower provider densities. Some limitations in the study included the 
lack of diversity and the inability to synchronize the Vermont mortality data registry from 2017-
2019 to the date buprenorphine providers received their x-waiver.    
     
Conclusion  
Further evaluation needed of the buprenorphine program in Vermont and the impact of other 



























Over the last two decades, rates of opioid abuse and opioid-related overdose deaths 
have significantly increased across the United States.1 More than 49,000 people died from 
opioid misuse in 2017 alone.2 Opioid use disorders (OUD) have tragically impacted individuals, 
families, and communities across the United States through increased crime and violence, and 
expanded health care costs.3  
Previous research has shown that medication assisted treatment (MAT), which is the 
combination of opioid substitution medication and counseling, is more effective at reducing 
morbidity and mortality associated with OUD than using time-limited medication, abstinence, 
or psychosocial interventions.1,4 Through the expansion of the Buprenorphine Waiver Program, 
providers who complete training to obtain an x-waiver are allowed to prescribe buprenorphine 
to patients in other clinical settings rather than limiting this service to opioid treatment 
programs.5 Despite these interventions, only a small percentage of patients who need 
treatment for OUD actually receive it.5     
Access to buprenorphine services through waivered providers is not distributed evenly 
across the United States as many of them practice primarily in urban areas.5,6 Additionally, 
buprenorphine providers are only allowed to prescribe to a set number of patients for the first 
year of having their x-waiver, with incremental increases for each subsequent year. Rural 
counties have a lower supply of buprenorphine-prescribing physicians per 100,000 
residents.6 Vermont is a small and rural state with varying levels of buprenorphine providers by 
county.7,8  
This research study addressed the following questions: Is the number of buprenorphine 
providers associated with the number of opioid related deaths per county?; and does a rural 
setting in Vermont affect mortality rates due to a possible lack of buprenorphine 
providers? The objective of this research was to examine if overdose mortality is impacted by 




This study was a cross-sectional analysis of overdose deaths per county in Vermont from 
2017-2019. The dataset was obtained from the Vermont Electronic Death Registration System 
and consisted of individuals whose primary cause of death was listed as illicit drug poisoning, 
illicit opioid poisoning, prescription opioid poisoning, other pharmaceutical poisoning, and all 
opioid poisoning. These causes correspond with ICD-10 codes, X40, X41, X42, X43, X44, X60, 
X60, X61, X62, X63, X64, X85, Y10, Y11, Y12, Y13, or Y14.     
A map of Vermont buprenorphine providers and treatment centers per county was 
accessed from the Vermont Department of Health (VDH). Treatment directory and resource 
guides listed on the VDH website were posted as of October 30, 2017; only deaths occurring in 
2017, 2018, and 2019 were included in our analysis to align time frames. Proximity to treatment 
was based on town where the death occurred. Three treatment options in New 
Hampshire accessible to Vermont residents were excluded from the study.        
Vermont Death Registry from 2015 to 2019 contained death information for 26,738 
individuals. After excluding deaths that did not occur in our time frame or have a primary cause 
of death as previously stated, 365 valid cases were left. After further examination of the 
remaining dataset three additional cases were excluded due to a lack of City Town Code (CTC), 
leaving 362 valid cases.   
Data were stratified among 2017-2019 deaths to include the underlying cause of death, 
as described above, per county. The incidence of overdose deaths per county was then 
compared to the number of buprenorphine providers per county, as listed on 
the VDH website. Statistical testing used ANOVA (IBM SPSS) with Tukey 
and Bonferroni post hoc comparisons (alpha level was 0.05). The University of Vermont 
Institutional Review Board has reviewed this project and determined that it qualifies as exempt 
from additional review.     
 
RESULTS 
 Visual analysis of the data shown in Figure 1 indicates no linear association between the 
number of overdose deaths and the number of available buprenorphine providers in a given 
Vermont county. As shown in Figure 1, there is a wide distribution between the number of 
deaths per county of residence and the number of buprenorphine providers per county per 
10,000 residents. The vertical lines along the X-axis refer to the percentile breakdown of cases 
into low, medium and high provider density, and these different provider density groups were 
used in further analysis.   
 
Figure 1:  
 
When stratifying data by provider density into high, medium, and low-density per capita 
groups, similar results were shown. A univariate analysis was run on each group to determine 
impact of provider density on overdose deaths, and a one-way ANOVA test was then run to 
determine the mean difference in deaths between low, medium, and high provider density 
counties. The average number of deaths was higher in medium provider density counties than 
in high and low provider density counties, with medium provider density counties averaging 
62.97 deaths per 10000 residents, high density counties averaging 38.00 deaths per 10000 
residents and low provider density counties averaging 32.73 deaths per 10000 
residents. Tukey and Bonferroni tests of association between groups yielded similar results as 
shown in table 1, with statistically significant differences in mean deaths between medium-
density counties and high-density counties (p-value <.001) and between medium-density 
counties and low-density counties (p-value <.001). These post-hoc tests were both run to 
control for type 1 error rates between groups, with both tests resulting in similar mean 
differences between groups. Sex, veteran status, marital status were determined to be 
potential confounders and univariate analyses of variance tests of between-subjects 
effects were run to determine significance. However, none of the variable were determined 
have a statistically significant impact on the average number of deaths per provider density 
grouping (p-values 0.519, 0.261, 0.957 respectively). As shown in table 1, there was not 
a statistically significant difference in mean deaths between the low and high provider density 






Our study found counties with medium provider densities (3.56-4.07 providers per 
10,000 residents) had a higher number of overdose deaths. Counties with high (over 4.08 
providers per 10,000 residents) and low provider densities (1-3.55 providers per 10,000 
residents) had comparatively lower rates of overdose deaths.      
Vermont has one of the highest capacities to treat OUD in the nation with 10.56 people 
in treatment per 1,000.7 Nationally, the majority of providers with a buprenorphine waiver 
practice in urban counties, which leaves rural counties without access to outpatient treatment 
for OUD.6 Interestingly, we found that the counties in Vermont with the highest provider 
densities (Caledonia, Essex, and Orange) were among the least populous counties and the most 
populous county, Chittenden, had medium provider density.     
Studies have shown obtaining a buprenorphine waiver alone does not mean a provider 
will prescribe to patients, with only 75% of waivered providers treating patients since obtaining 
their waiver.6 Waivered providers have also been shown to treat fewer patients than their 
approved patient-limit capacity.5 Vermont has adopted a hub and spoke system and increased 
the number of buprenorphine providers, but it does not directly ensure patients will receive 
treatment. Further investigation of buprenorphine provider utilization, number of patients in 
treatment per provider, and disparities in access to providers needs to be evaluated.      
This study is limited by several factors. Due to Vermont’s aging population, there may be 
lower rates and distribution of drug-related fatalities.8 Vermont is also one of the whitest states 
in the US and subsequently this study was unable to stratify results by race or ethnicity. 
Chittenden County is also the largest county in Vermont with more than twice 
the population density compared to the second most populous county, and this variation could 
have skewed data.      
Additionally, mortality data was used to compare overdose death and buprenorphine 
provider density. Individuals may have sought treatment anywhere in Vermont and the VDH 
provider map lists three treatment options which are in New Hampshire. Finally, this study was 
unable to synchronize the Vermont mortality data registry from 2017, 2018, and 2019 with the 
date providers received their waiver, thus their scope of practice is unknown at the time of 
associated mortalities.     
Vermont has made tremendous strides in increasing the capacity to treat patients with 
OUD – Further evaluation of treatment for OUD from Vermont buprenorphine providers is 
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